Replace The HumansAI agents & platforms, verified

PathAI

AI platform and FDA-cleared digital pathology tools (AISight Dx1) for cancer diagnostics and pharma drug-development biomarker analysis; acquired by Roche in 2026.

Acquiredhigh confidenceVerified 2026-08-01

This is where the depth lives — everything below is evidence-graded

How the product is positioned

AI platform and FDA-cleared digital pathology tools (AISight Dx1) for cancer diagnostics and pharma drug-development biomarker analysis; acquired by Roche in 2026.

Our summary of the vendor’s positioning — verbatim claim not yet recorded

What we found

Level 2 · augmentative

Completes the unit of work end to end without a person producing it, but a radiologist must sign the report; FDA clearances in this category are for assistive use. That checkpoint is imposed from outside the product, not configured within it.

The human checkpoint here is imposed by regulation — it is not a setting that can be turned off.

Graded 2026-08-01 · re-check 2026-11-01

Procurement detail

Deployment
saasvendor documentation
Compliance
HIPAA · FDA-cleared (AISight Dx1) · EMA/FDA-qualified AI Drug Development Tool (AIM-MASH)report dates not disclosed — request before signing
Integrations
Labcorp digital pathology network claim unverifiedlab information systems claim unverified
Pricing
platform-licenseNot publicly listed.
Human checkpoint
Requiredregulatory, not configurable
Named customers
Labcorpfrom cited sources

Will they still be here?

Acquired
Funding
Acquired by Roche: $750M upfront plus up to $300M in milestones (2026), integrating into Roche Diagnostics in H2 2026; previously raised $241M across 8 rounds
Founded
2016
HQ
Boston, USA
Ownership
Acquired by Roche: $750M upfront plus up to $300M in milestones (2026), integrating into Roche Diagnostics in H2 2026; previously raised $241M across 8 rounds

Sources

Logo retrieved 2026-08-01from the vendor’s own site · trademark of Roche Diagnostics (formerly PathAI, Inc.)

Where it’s weak

Now a Roche subsidiary, so independent roadmap and open-platform ambitions are subject to Roche's diagnostics strategy.

Corrections

Vendors may submit factual corrections free of charge. We correct facts and publish the change. We do not accept payment to change a grade. Submit a correction →